Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Otsuka, Bristol-Myers Squibb announce six-year data from SPRYCEL Phase 3 trial on CP-CML

Third Rock Ventures announces formation of Global Blood Therapeutics

Third Rock Ventures announces formation of Global Blood Therapeutics

Study strengthens link between HHV-6B and mesial temporal lobe epilepsy

Study strengthens link between HHV-6B and mesial temporal lobe epilepsy

Sabin initiates novel human hookworm vaccine Phase 1 clinical trial

Sabin initiates novel human hookworm vaccine Phase 1 clinical trial

Researchers shed light on key biological events that may lead to new disease treatments

Researchers shed light on key biological events that may lead to new disease treatments

Pioneering new test can quickly diagnose coeliac disease

Pioneering new test can quickly diagnose coeliac disease

New technique accurately determines infants at risk for malaria

New technique accurately determines infants at risk for malaria

Iron and micronutrient-enriched foodstuffs can fight against anaemia

Iron and micronutrient-enriched foodstuffs can fight against anaemia

Bayer announces updated data from radium-223 dichloride Phase III trial on CRPC

Bayer announces updated data from radium-223 dichloride Phase III trial on CRPC

Lilly announces final results from ALIMTA Phase III study on NSCLC

Lilly announces final results from ALIMTA Phase III study on NSCLC

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Aeterna Zentaris announces results from perifosine Phase 3 trial on colorectal cancer

Aeterna Zentaris announces results from perifosine Phase 3 trial on colorectal cancer

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Genentech’s T-DM1 Phase III study on HER2-positive mBC meets primary endpoint

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Top-line results from Alnylam’s ALN-RSV01 Phase IIb trial on RSV infection

Cabazitaxel offers added benefit for men with metastatic prostate cancer

Cabazitaxel offers added benefit for men with metastatic prostate cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.